The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AGILENT TECHNOLOGIES INC. | COM | 00846U101 | 26,211 | 460,000 | SH | SOLE | 460,000 | 0 | 0 | ||
| AMGEN INC | COM | 031162100 | 16,855 | 120,000 | SH | SOLE | 120,000 | 0 | 0 | ||
| ARIAD PHARMACEUTICALS INC | COM | 04033A100 | 69,390 | 12,850,000 | SH | SOLE | 12,850,000 | 0 | 0 | ||
| AVEO PHARMACEUTICALS INC | COM | 053588109 | 2,854 | 2,570,759 | SH | SOLE | 2,570,759 | 0 | 0 | ||
| BIO-REFERENCE LABS INC | COM $.01 NEW | 09057G602 | 35,944 | 1,280,984 | SH | SOLE | 1,280,984 | 0 | 0 | ||
| ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 4,155 | 105,000 | SH | SOLE | 105,000 | 0 | 0 | ||
| INTRA CELLULAR THERAPIES INC | COM | 46116X101 | 4,936 | 360,000 | SH | SOLE | 360,000 | 0 | 0 | ||
| KINDRED BIOSCIENCES INC | COM | 494577109 | 3,608 | 390,000 | SH | SOLE | 390,000 | 0 | 0 | ||
| MERCK & CO INC NEW | COM | 58933Y105 | 23,712 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
| ONCONOVA THERAPEUTICS INC | COM | 68232V108 | 1,505 | 350,000 | SH | SOLE | 350,000 | 0 | 0 | ||
| QUEST DIAGNOSTICS INC | COM | 74834L100 | 47,027 | 775,000 | SH | SOLE | 775,000 | 0 | 0 | ||
| REPROS THERAPEUTICS INC | COM NEW | 76028H209 | 11,210 | 1,132,367 | SH | SOLE | 1,132,367 | 0 | 0 | ||
| TARGACEPT INC | COM | 87611R306 | 1,594 | 630,000 | SH | SOLE | 630,000 | 0 | 0 | ||
| VIVUS INC | COM | 928551100 | 9,935 | 2,573,943 | SH | SOLE | 2,573,943 | 0 | 0 | ||